Metsera
The price of the weight-loss miracle drug has dropped from $1,350 per month to $350. The GLP-1 market will shift from a duopoly in the United States to multi-dimensional competition.
Recently, Eli Lilly and Nord Agreement reached with the US government on GLP-1 weight loss drug Significant price reduc...
Stock
2026-01-12
Like a business war epic! The latest developments in the battle for the "rising star of weight-loss drugs" among industry giants are here!
[Introduction] Pfizer An amendment to the merger agreement with Metsera was reached, valuing Metsera at up to $86.25 pe...
Stock
2026-01-12
A crucial bidding war for weight-loss drugs: Pfizer may raise its bid to compete with Novo Nordisk for Metsera.
The bidding war surrounding obesity biotechnology company Metsera is intensifying, with reports indicating that Pfizer....
Stock
2026-01-12
Novo Nordisk's "hijacking" of Pfizer's acquisition sparks a surge in the valuation of weight loss therapy assets.
On October 31, Pfizer For US weight loss drug manufacturer Metsera and Danish pharmaceutical giant Novo Nordisk Novo No...
Stock
2026-01-12
Novo Nordisk outbids Pfizer for $4.9 billion to acquire US company Metsera.
①Novo Nordisk, the Danish pharmaceutical giant ① Novo Nordisk made an all-cash offer of $56.50 per share to acquire the...
Stock
2026-01-12